Short interest for CMTSU Liquidation gives investors a sense of the degree to which investors are betting on the decline of CMTSU Liquidation's stock. Short interest data is updated every two weeks.

CMTSU Liquidation Stock (OTC:CBRI), Short Interest Report

CMTSU Liquidation Inc is an information technology consulting and services company. It provides information technology services globally, mainly in groups which include Independent software vendor relationships, Ciber managed services, Business consulting, Application development and Management services and Software as a service offering. Its services portfolio includes cloud, mobile, business intelligence, digital transformation etc. The firm has North America and International segments. It derives the majority of its revenues from North America segment. The company offers its services to industries such as Financial Services, Logistics, Healthcare, and Manufacturing.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ABWN

AGTK

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AQMS

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATHX

ARTEMIS THERAPEUTICS INC by Artemis Therapeutics, Inc.

ATMS

ATYG

BGFT

BLOZF

BOIRF

BWLVF

CBRI

CCGN

CHMR

CMGHF

COCP

CORV

COTE

CSPUF

DVLY

DYLLF

ECOR

ELGX

FERL

FINCANNA CAPITAL CORP by Fincanna Capital Corp.

FNNZF

FUAPF

FVGCF

FVVSF

GGBXF

GLBS

GTBP

GURE

HEMP

HESG

HGEN

HKTTF

HUABF

HVBTF

ICABY

IPSEY

ISIG

IWSY

KINS

KRKR

LATF

LFUGF

LFUGY

MCET

MDIN

MGXMF

MIST

MLXEF

MMJJF

MOAEF

NHNKY

NIMU

NXTTF

OCANF

OGDCF

OLVRF

PARNF

PHAT

PHTCF

PHUN

PMSO

PRTR

PSIX

QBAN

QEGY

QOIL

RETC

RKAGY

RTTR

RVLT

SEED

SEEK

SFEG

SING

SNNAF

SPVNF

SUIC

TBEV

TGIFF

TLGN

TLRY

TOCA

TRPX

TWMC

UBQU

UVSE

VFRM

VGGOF

VREOF

VVCIF

WDDMF

WHITF

ICC INTL CANNABIS CORP by ICC Intl Cannabis Corp.

WLDCF

Stocks That Hit 52-Week Lows On Wednesday

CMTSU LIQUIDATION INC by CMTSU Liquidation Inc.

CMTSU Liquidation Inc

XWELL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today announced the introduction of IV hydration drip therapy at its Miami International Airport (MIA) XpresSpa&#xAE; location. In partnership with Revitalize IV Lounge ("Revitalize"), the new service, which offers a fast and efficient way to deliver vitamins, minerals, and amino acids directly into the bloodstream, is available in MIA's North Terminal, Concourse D, Gate D-11. &nbsp;
"A popular and effective treatment to replenish our body's essential nutrients, IV hydration drip therapy is a compelling addition to our XpresSpa menu of services and provides yet another opportunity to drive more revenue at higher margins," said XWELL CEO, Scott Milford. "Miami is a great location for us to pilot Revitalize's IV drips, with the intention of expanding to other U.S. markets."
IV hydration drip therapy ensures rapid absorption and replenishment of fluids and helps to boost energy levels, aid in recovery from jet lag, and enhance recovery from illness or strenuous activity. The XpresSpa location in Miami currently offers four IV hydration drip therapy options to its customers:
<ul>
<li>Jet Lag Xpress: A blend of trace minerals and B-complex vitamins help regulate circadian rhythm sleeping patterns, boost mental performance, and help travelers stay sharp and focused.</li>
<li>Myer's Cocktail: The perfect blend of multivitamins and hydration, it helps alleviate chronic symptoms like inflammation, muscle pain, fatigue, and stress.</li>
<li>Ultimate Xpress: This potent vitamin blend enhances the immune system, detoxifies the body, increases energy levels, and restores hydration.</li>
<li>Xpress Recovery: Get instant hangover relief with a high dose of vitamins and minerals that help hydrate the body and replenish electrolytes.</li>
</ul>
XpresSpa's IV hydration drip therapies can be administered in as little as 20 minutes with prices starting at $220 per session.
The introduction of Revitalize's IV hydration drip therapies in Miami underscores recent growth across the XWELL portfolio including the launch of Clockwork MiNiCURE robotic manicures at Harry Reid International Airport in Las Vegas (LAS), Miami International Airport (MIA) and John F. Kennedy International Airport (JFK), the introduction of Stretch services, and the expansion of fully autonomous massage chairs by HydroMassage and Human Touch&#xAE;. XWELL also recently opened an XpresSpa location in Abu Dhabi and announced plans to open a tech-forward, labor-lite location in New York City's Penn Station.
For more information about XpresSpa, visit <a href="https://www.globenewswire.com/Tracker?data=Ch-gUPwHcylblTq6ZNYC-fmsVbSI1e8JteEkMdCUWaR477NWyhuXuLXZiVWdspLjB7vj1pxalYnB9s25e4ErThFT7J5BKK7dFYVIEnmdZLc=">www.xpresspa.com</a>.

XWEL

XpresSpa Introduces IV Hydration Drip Therapy At Miami International Airport

WIIM

WOLF

Wolfspeed shares are trading lower after the company reported worse-than-expected Q3 revenue results. Also, TD Cowen downgraded the stock from Buy to Hold and Mizuho lowered its price target from $30 to $27.

Real Estate

NLOP

Net Lease Office Properties Announced The Sale Of The Following Three Office Properties In March And April For Gross Proceeds Totaling Approximately $131.6M

Share Repurchase Plan
In addition, the Company today announced that its Board of Directors has authorized a new one-year share buyback plan allowing the Company to invest up to $15 million to repurchase its ordinary shares. This plan will take effect as soon as the previously-announced $15 million one-year plan is completed. The timing and actual number of shares repurchased will depend upon a variety of factors, including share market price and general business and market conditions. The plan authorizes management to repurchase ordinary shares using a variety of methods, including open market transactions in compliance with the rules of the US Securities and Exchange Commission and other applicable legal requirements. Repurchases will be funded from available working capital. The plan does not obligate Silicom to buy back any specific number of shares and may be suspended or terminated at any time at Management's discretion. Management notes that its cash balance provides sufficient working capital and financial flexibility to weather the current environment while completing the Company's current share buyback program and carrying out this new one.

Buybacks

SILC

Silicom Board Of Directors Has Authorized A New One-year Share Buyback Plan Allowing The Company To Invest Up To $15M To Repurchase Its Ordinary Shares

Contracts

V2X Awarded Firm-Fixed Price Contract Valued At $88M

U.S. stock futures were higher this morning, with the Dow futures gaining over 150 points on Thursday.
Shares of Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/05/38565528/etsy-q1-earnings-revenue-miss-eps-miss-challenging-macroeconomic-environment">first-quarter financial results</a>.
Etsy reported first-quarter revenue of $645.954 million, which missed the consensus estimate of $646.33 million, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. The company reported quarterly earnings of 48 cents per share, which missed estimates of 49 cents per share.
Etsy shares tumbled 13.2% to $60.45 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) shares dipped 31.8% to $8.82 in pre-market trading after the company reported first-quarter financial results. The company said it expects second-quarter revenue in a range of $130 million and $134 million, versus the $140.16 million analyst estimate.</li>
<li>Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) shares tumbled 28.6% to $13.02 in pre-market trading after the company reported first-quarter financial results and announced a CEO transition. Baird analyst Rob Oliver downgraded Freshworks from Outperform to Neutral and lowered the price target from $28 to $16.</li>
<li>Remitly Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) shares declined 16.7% to $14.58 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) dipped 12.5% to $111.50 pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>CytomX Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares fell 12.7% to $4.48 after jumping 215% on Wednesday.</li>
<li>Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares declined 11.3% to $23.15 in pre-market trading following weak quarterly sales.</li>
<li>Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) shares dipped 10.6% to $100.00 in pre-market trading following weak first-quarter guidance.</li>
<li>Paycom Software Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) shares fell 9.3% to $169.00 in pre-market trading following weak second-quarter guidance.</li>
<li>Hudson Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) shares fell 8.2% to $9.00 in pre-market trading following first-quarter results.</li>
<li>Appian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) shares declined 7.4% to $34.00 in pre-market trading after the company reported worse-than-expected first-quarter earnings and updated FY24 outlook.</li>
<li>Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) shares declined 6.5% to $39.19 pre-market trading after the company reported its first-quarter financial results.</li>
<li>Schrodinger Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) shares declined 5.8% to $23.80 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Prudential Financial Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) shares fell 5.4% to $106.29 in pre-market trading following downbeat earnings.</li>
<li>eBay Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) shares fell 3.4% to $49.35 in pre-market trading after the company reported first-quarter financial results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38573088/apple-kellanova-and-3-stocks-to-watch-heading-into-thursday">Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Pre-Market Outlook

APPN

CTMX

DASH

EBAY

ETSY

FRSH

FSLY

HDSN

PAYC

QRVO

RELY

SDGR

Etsy Reports Downbeat Earnings, Joins Fastly, DoorDash And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Guidance
Management projects that revenues for the second quarter of 2024 will range from $15 million to $17 million. We believe that excess customer inventories and global economy headwinds will ease moving forward through 2024, resulting in second half revenues that are higher than those of the first half, and full-year revenues of approximately $70 million.

Guidance

Silicom Sees Q2 Revenue $15M-$17M; FY24 Revenue ~$70M

Remitly Global shares are trading lower after the company reported mixed Q1 financial results.

Health Care

Tech

Wipro Has Been Selected By Independent Health, Western New York's 5-star Rated Medicare Advantage Plan, To Implement Wipro's Medicare Prescription Payment Plan Platform For The Upcoming Open Enrollment Period

Wedbush analyst Jay McCanless reiterates Green Brick Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRBK#NYSE">GRBK</a>) with a Neutral and maintains $49 price target.

Price Target

Reiteration

Analyst Ratings

GRBK

Wedbush Reiterates Neutral on Green Brick Partners, Maintains $49 Price Target

Silicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILC#NASDAQ">SILC</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.23) by 65.22 percent. This is a 162.3 percent decrease over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $14.37 million which missed the analyst consensus estimate of $16.73 million by 14.14 percent. This is a 61.36 percent decrease over sales of $37.18 million the same period last year.

Earnings

Earnings Misses

Silicom Q1 Adj $(0.38) Misses $(0.23) Estimate, Sales $14.37M Miss $16.73M Estimate

Jefferies analyst Dushyant Ailani maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Buy and raises the price target from $209 to $211.

FSLR

Jefferies Maintains Buy on First Solar, Raises Price Target to $211

The Trade Desk shares are trading higher after VerticalScope Holdings announced that it adopted the company's OpenPass and OpenPath solutions. Also, Jefferies upgraded the stock from Hold to Buy and raised its price target from $95 to $105.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbioaffinitytech.com%2F&amp;esheet=53970614&amp;newsitemid=20240502141417&amp;lan=en-US&amp;anchor=bioAffinity+Technologies&amp;index=1&amp;md5=6212cc11f33e67a0007884b358823576">bioAffinity Technologies</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>, BIAFW))) shares recent Company news.
CyPath&#xAE; Lung Sales Ramp Up Month over Month
Sales of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cypathlung.com%2F&amp;esheet=53970614&amp;newsitemid=20240502141417&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=2&amp;md5=1275248c3bfd28c68d209e2bdb85ce69">CyPath&#xAE; Lung</a>, our noninvasive diagnostic test for the early detection of lung cancer, continue to climb, with April sales up 21% over March. Physicians outside of Texas are also signing up with our wholly owned subsidiary, Precision Pathology Laboratory Services, to order CyPath&#xAE; Lung for their patients. In addition to Texas, pulmonologists in New Jersey, Pennsylvania, Michigan and North Carolina have ordered CyPath&#xAE; Lung diagnostic tests for their patients with pulmonary nodules.
CyPath&#xAE; Lung Sales, Support Teams Continue to Grow
bioAffinity Technologies' National Sales Director Dallas Coleman announced that Jackie Kennedy has joined the Company as Pulmonary Sales Executive for CyPath&#xAE; Lung in the San Antonio/Austin market. Ms. Kennedy previously worked for Pulmonx Corporation, a provider of minimally invasive treatments for chronic obstructive pulmonary disease (COPD). In addition to Pulmonx, she has worked at Philips Healthcare, Baxter Healthcare, and Evologics America. "We are excited to welcome Jackie to the team at a pivotal time in the product launch for CyPath&#xAE; Lung," Mr. Coleman said. "In her two decades of experience in healthcare sales and marketing, she has built and maintained strong customer relationships and consistently exceeded her sales targets."
We are also pleased to announce that Jessica Alarcon has joined the Company as our newest Patient Coach for CyPath&#xAE; Lung. Ms. Alarcon provides a personal touch for patients who have questions about collecting a sputum sample. "Patients have told us how much they appreciate having a Patient Coach who can walk them through the collection process," bioAffinity Technologies President and CEO Maria Zannes said. "Jessica brings multi-faceted experience to this very important position, where she shares her insight and empathy for our patients at high risk for lung cancer."
bioAffinity To Present at American Thoracic Society's Annual Conference
bioAffinity Staff Scientist Lydia Bederka, Ph.D., is heading to San Diego this month to present research, "Sputum Versus Bronchoalveolar Lavage (BAL) Fluid on a Flow Cytometric Platform," at the 2024 American Thoracic Society (ATS) International Conference. Dr. Bederka will present research conducted in the development of a diagnostic test that uses BAL fluid to detect lung cancer. The ATS conference brings 14,000 clinicians and researchers in pulmonology, critical care and sleep medicine together to share ideas and innovations.

Biotech

BIAF

bioAffinity Technologies News Update, CyPath Lung Sales Ramp Up Month Over Month

The company will use its production prototype aircraft to prepare for upcoming for-credit flight testing.

JOBY

Joby Says Completed Its Pre-production Flight Test Program And Is Now Focused On Next Phase Of Flight Testing

Wedbush analyst Richard Anderson maintains Boston Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) with a Neutral and lowers the price target from $66 to $63.

Wedbush Maintains Neutral on Boston Props, Lowers Price Target to $63

STTK

Shattuck Labs Cash And Cash Equivalents And Investments Of $114.6M For The Quarter Ended March 31, 2024,  Will Be Sufficient To Fund Its Operations Into 2026

Jefferies analyst James Heaney assumes Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Hold rating and announces Price Target of $4.

Initiation

Jefferies Assumes Outbrain at Hold, Announces Price Target of $4

Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developers
Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.
Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.criver.com%2Fproducts-services%2Fcell-and-gene-therapy-cdmo-solutions%2Fplasmid-and-viral-vector-products%2Faav-products%2Faav-reference-materials-empty-capsids%3Fregion%3D3601&amp;esheet=53969344&amp;newsitemid=20240502084745&amp;lan=en-US&amp;anchor=empty&amp;index=1&amp;md5=a63d526c85cf45721edc2be03b1977a9">empty</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.criver.com%2Fproducts-services%2Fcell-and-gene-therapy-cdmo-solutions%2Fplasmid-and-viral-vector-products%2Faav-products%2Faav-reference-materials-full-capsids%3Fregion%3D3601&amp;esheet=53969344&amp;newsitemid=20240502084745&amp;lan=en-US&amp;anchor=full&amp;index=2&amp;md5=13ba7c33fc23b9a3a46c3ed64478d772">full</a> capsid ratios and high vector genome concentration (GC/mL), plus five <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.criver.com%2Fproducts-services%2Fcell-and-gene-therapy-cdmo-solutions%2Fplasmid-and-viral-vector-products%2Flentivirus-products%2Flentiviral-controls&amp;esheet=53969344&amp;newsitemid=20240502084745&amp;lan=en-US&amp;anchor=LVV+reference+material&amp;index=3&amp;md5=bf343ce70978c09d554258afe79e3d2b">LVV reference material</a> products, available with different combinations of promoters and reporter genes. The additional reference materials add to the Company's extensive portfolio of plasmid and viral vector contract development and manufacturing organization (CDMO) offerings, reinforcing its concept-to-cure commitment to CGT researchers and developers by enabling partners to navigate the path from early discovery to commercial.

Charles River Launches Viral Vector Reference Materials To Streamline the Transition To GMP

CRWD

CrowdStrike, Tata Consultancy Services Ink Global Strategic Partnership To Transform Modern Enterprise Cybersecurity

CMTSU Liquidation